“Latest Stem Cells News”

An experimental drug currently being tested against breast and lung cancer shows promise in fighting the brain cancer glioblastoma and prostate cancer, researchers at UT Southwestern Medical Center have found in two preclinical studies.

The drug’s actions, observed in isolated human cells in one trial and in rodents in the other, are especially encouraging because they attacked not only the bulk of the tumor cells but also the rare cancer stem cells that are believed to be responsible for most of a cancer’s growth, said Dr. Jerry Shay, professor of cell biology and a senior co-author of both papers. The glioblastoma study appears in the January issue of Clinical Cancer Research. The prostate cancer study is available online in the International Journal of Cancer.

(…) Participation in this drive and thus registration with the National Marrow Donor Program consists of simple swabs of the cheeks using Q-tips for a DNA test. DNA information is entered into this lifesaving donor program database. If a potential donor is identified as a potential match for David or someone else in need, he/she will be contacted by the donor program to have a small amount of blood drawn for lab testing.

If that person is then confirmed as a match, he/she will be asked to provide stem cells through a simple donation procedure where blood is taken from one arm through a needle and run through a machine, which separates the stem cells from the blood, and returned into the other arm.

Myelodysplastic Syndromes (MDS) are a group of diseases that affect the bone marrow and blood. Some types of MDS are mild and easily managed, which other types are severe and life-threatening. Mild MDS can grow more severe over time. It can develop into a fast-growing, severe leukemia called acute myelogenous leukemia. Stem cell transplant is the only treatment that can cure MDS.

In this treatment, the patient receives high-dose chemotherapy and/or total body irradiation to kill the cells in the bone marrow (including the abnormal bone marrow cells). The patient would then receive new functioning blood-forming stem cells harvested from the donor (…)

from http://www.nj.com/warrenreporter/index.ssf/2009/11/centenary_college_to_hold_stem.html

The drug metformin, a mainstay of diabetes care for 15 years, may have a new life as a cancer treatment, researchers said.
In a study in mice, low doses of the drug, combined with a widely used chemotherapy called doxorubicin, shrank breast-cancer tumors and prevented their recurrence more effectively than chemotherapy alone.

The findings add to a growing body of evidence that metformin, marketed as Glugophase by Bristol-Myers Squibb Co. and available in generic versions, could be a potent antitumor medicine.
They also lend support to an emerging theory that cancer’s ability to survive and resist therapy is regulated by cancer stem cells that drive a tumor’s growth and survival.

Chemotherapy is effective against many tumors, said Kevin Struhl, a Harvard Medical School researcher and principal investigator of the study. “The problem is cancer stem cells acquire resistance” to treatment, he said. “They are able to regenerate the tumor and as a result you end up with a relapse.”
About 5% to 10% of a tumor’s cells are believed to be cancer stem cells, he said.

In the report, being published in the Oct. 1 edition of Cancer Research, a journal of the American Association for Cancer Research, researchers said the combination of metformin and doxorubicin killed both regular cancer cells and cancer stem cells.
In contrast, doxorubicin alone had limited effect on the stem cells.

(…)

read more on http://online.wsj.com/article/SB10001424052970203278404574413273870984920.html

For children born with immunodeficiencies, researchers may have found a better way for them to get the help they need from stem-cell transplants (…)

Children with primary immunodeficiencies have genetic defects in their immune system that leave them open to infection and other complications. Stem-cell transplants can replace the defective immune system with one derived from healthy donor bone marrow, but without a stem-cell transplant, many of these children might die, the researchers noted in a journal news release.

In order to create space for the donor stem cells and prevent rejection, the patient usually undergoes chemotherapy, radiotherapy or both. This chemoradiotherapy can cause severe liver or lung damage, as well as hair loss and sickness. It may also cause problems with growth, puberty and infertility in later life, according to the news release (…)

With this approach, the 16 children with primary immunodeficiencies in this study, who were too sick for a traditional stem-cell transplant, were able to avoid much of the toxicity caused by chemotherapy (…)

read full article on http://www.ajc.com/health/content/shared-auto/healthnews/bird/630592.html

Plerixafor has allowed doctors to collect stem cells from patients where there had been previous difficulties.
The drug, which has only recently been licensed, is being used at the Beatson West of Scotland Cancer Centre.

Stem cells therapies are used to treat people with cancer of the blood. The cells are collected and reintroduced to a patient after chemotherapy.
Doctors often encounter problems collecting enough stem cells from about one in 10 cancer patients to undergo treatment.

Plerixafor has, so far, had a 100% success rate in allowing doctors at the cancer centre to collect enough cells from patients who fall into this category.
Blood specialist, Dr Kenneth Douglas, explained how the drug worked.

“Basically it blocks a chemical scent that stem cells sniff for that tells them they’re in the bone marrow,” he said.
“If you block that chemical scent they get confused and agitated and they think they are not in the bone marrow any more and they start wandering into the blood stream looking for the bone marrow.”

When more stem cells “start wandering into the blood” doctors are able to collect them for future treatment.
One patient who has benefited from this approach is retired professional golfer, Billy McCondachie.

He said his age was a barrier to potential stem cell treatment.
“We were only able to get about half of my stem cells out until Dr Douglas came along with this new drug,” he said.

“One could say that pretty much saved my life.”
The centre in Glasgow has now treated 13 people with the drug and every one has been able to proceed with stem cell treatment.

from BBC news

Italian Welfare Undersecretary Ferruccio Fazio disapproves of private biobanks and is clearly in favor of the “allogenic” conservation of umbilical cord stem cells, meaning the conservation of stem cells saved for the exclusive use of the donor-patient. Speaking about a government report on “the appropriate use of umbilical cord stem cells”, Fazio outlined the government’s approach on the issue. A few weeks after a ministerial decree dictating new regulations for umbilical cord conservation, Fazio explained autologous donation, meaning conservation of stem cells for yourself, “is not only less useful, but also less efficient as science has demonstrated”.

The only exception allowed by the ministerial decree is “the conservation of umbilical cord blood to be used by families with children who are at risk for diseases that are genetically determined, which are scientifically proven and clinically approved to be treated with umbilical cord stem cells upon presenting clinical documentation released by a specialist”. From a scientific standpoint, underlined Fazio, “the use of hematopoietic stem cells for allogenic transplants creates another advantage because these stem cells eliminate diseased cells that remain after chemotherapy or radiotherapy, thanks the ability of special white blood cells from the donor to recognize them as foreign and destroy the residual diseased cells, performing an actual ‘cellular therapy’. This effect of hematopoietic stem cells transplants is known as ‘Graft versus Leukemia’.